Tag: Drug
-
Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 studyBRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ — Continuity Bios…
-
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to…
-
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 /PRNewswire/ — The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents …
-
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. The development and manufacturing activities are being conducted at Piramal’s dedicated sterile injectable facility in Lexington, Kentucky. This partnership addresses ongoing cycl…
-
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal’s commitment to reduce Scop…
-
EMPE Diagnostics to Unveil CircuLOK Product Range at NATCON 2026, Expanding Access to TB Drug-Resistance Diagnostics
STOCKHOLM, Sept. 10, 2026 /PRNewswire/ — EMPE Diagnostics AB today announced it will unveil the CircuLOK product range at the 81st National Conference on Tuberculosis and Chest Diseases (NATCON 2026), taking place 1–4 October in Patiala, India. The launch expands EMPE’s TB molecular resistance-test…
Latest News
About the Author
Publicize Your Brand
Through our news networks, we raise millions of users’ awareness. We are among the world’s most reputable news networks.
